Podcast
Questions and Answers
What is a key feature of Essential Thrombocythemia (ET) that distinguishes it from Chronic Myeloid Leukemia (CML)?
What is a key feature of Essential Thrombocythemia (ET) that distinguishes it from Chronic Myeloid Leukemia (CML)?
- Increased megakaryocyte numbers in the bone marrow.
- The presence of giant platelets.
- The absence of the Philadelphia chromosome. (correct)
- Abnormal platelet function leading to haemorrhage.
Which of the following is NOT a common symptom associated with Essential Thrombocythemia?
Which of the following is NOT a common symptom associated with Essential Thrombocythemia?
- Splenomegaly.
- Erythromelalgia.
- Severe chest pain. (correct)
- Fatigue.
What is the typical range for platelet counts in patients diagnosed with Essential Thrombocythemia (ET)?
What is the typical range for platelet counts in patients diagnosed with Essential Thrombocythemia (ET)?
- 50-70 x 10^9/L
- 150-250 x 10^9/L
- 450-1000 x 10^9/L (correct)
- 1500-2000 x 10^9/L
Which of the following statements accurately describes the role of Hydroxycarbamide in treating Essential Thrombocythemia?
Which of the following statements accurately describes the role of Hydroxycarbamide in treating Essential Thrombocythemia?
Which of the following is a key characteristic of megakaryocytes in Essential Thrombocythemia?
Which of the following is a key characteristic of megakaryocytes in Essential Thrombocythemia?
What is the typical timeframe for Essential Thrombocythemia (ET) to remain stationary without progressing to other conditions?
What is the typical timeframe for Essential Thrombocythemia (ET) to remain stationary without progressing to other conditions?
Which of the following conditions is NOT considered a potential differential diagnosis for Essential Thrombocythemia?
Which of the following conditions is NOT considered a potential differential diagnosis for Essential Thrombocythemia?
What is the role of platelet-derived growth factor (PDGF) in the progression of Essential Thrombocythemia to Myelofibrosis?
What is the role of platelet-derived growth factor (PDGF) in the progression of Essential Thrombocythemia to Myelofibrosis?
Which disorder is NOT classified as a myeloproliferative disorder?
Which disorder is NOT classified as a myeloproliferative disorder?
The increased risk of transforming to acute leukemia is a common feature of which condition?
The increased risk of transforming to acute leukemia is a common feature of which condition?
What does the term 'clonal hematopoietic stem cell disease' imply in the context of myeloproliferative disorders?
What does the term 'clonal hematopoietic stem cell disease' imply in the context of myeloproliferative disorders?
At what age group is myeloproliferative disorders more commonly found?
At what age group is myeloproliferative disorders more commonly found?
Which of the following hematologic cell lines is NOT typically produced in excess in myeloproliferative disorders?
Which of the following hematologic cell lines is NOT typically produced in excess in myeloproliferative disorders?
What is a primary consequence of increased megakaryocyte activity in hematopoietic stem cells?
What is a primary consequence of increased megakaryocyte activity in hematopoietic stem cells?
Which of the following growth factors is involved in stimulating fibroblast activity related to myelofibrosis?
Which of the following growth factors is involved in stimulating fibroblast activity related to myelofibrosis?
What laboratory finding is characteristic of a leukoerythroblastic film?
What laboratory finding is characteristic of a leukoerythroblastic film?
Which treatment option is NOT typically used for managing myelofibrosis?
Which treatment option is NOT typically used for managing myelofibrosis?
What is one of the potential outcomes of untreated myelofibrosis?
What is one of the potential outcomes of untreated myelofibrosis?
Which mutation is commonly screened for in patients suspected of having myelofibrosis?
Which mutation is commonly screened for in patients suspected of having myelofibrosis?
What is a common clinical feature associated with myelofibrosis?
What is a common clinical feature associated with myelofibrosis?
What morphological feature is indicative of myelofibrosis in a peripheral blood smear?
What morphological feature is indicative of myelofibrosis in a peripheral blood smear?
Which of the following is NOT a major complication of hyperviscosity syndrome?
Which of the following is NOT a major complication of hyperviscosity syndrome?
What change occurs at the 617 position due to the JAK2 mutation in polycythaemia vera?
What change occurs at the 617 position due to the JAK2 mutation in polycythaemia vera?
In the diagnosis of polycythaemia vera, which combination fulfills the criteria outlined?
In the diagnosis of polycythaemia vera, which combination fulfills the criteria outlined?
Which of the following statements regarding treatment options for polycythaemia vera is TRUE?
Which of the following statements regarding treatment options for polycythaemia vera is TRUE?
What laboratory finding is associated with an increased risk of thrombosis in polycythaemia vera patients?
What laboratory finding is associated with an increased risk of thrombosis in polycythaemia vera patients?
Which molecular change is a common finding in all patients with polycythaemia vera?
Which molecular change is a common finding in all patients with polycythaemia vera?
Which of the following is NOT typically expected in the lab findings of a patient with polycythaemia vera?
Which of the following is NOT typically expected in the lab findings of a patient with polycythaemia vera?
Which of the following conditions is considered a secondary cause of increased red cell mass but is NOT a primary hematological disorder?
Which of the following conditions is considered a secondary cause of increased red cell mass but is NOT a primary hematological disorder?
Which mutation is primarily associated with Polycythaemia Rubra Vera (PRV)?
Which mutation is primarily associated with Polycythaemia Rubra Vera (PRV)?
What characterizes the blood condition referred to as 'absolute polycythaemia'?
What characterizes the blood condition referred to as 'absolute polycythaemia'?
Which condition is characterized by a BCR-ABL-1 fusion gene?
Which condition is characterized by a BCR-ABL-1 fusion gene?
What is a significant symptom of Polycythaemia Rubra Vera (PRV)?
What is a significant symptom of Polycythaemia Rubra Vera (PRV)?
What type of blood smear is primarily used to diagnose leukaemia?
What type of blood smear is primarily used to diagnose leukaemia?
Which statement correctly describes tyrosine kinase (TK) mutations in Polycythaemia Rubra Vera?
Which statement correctly describes tyrosine kinase (TK) mutations in Polycythaemia Rubra Vera?
Which of the following is NOT considered a component of myelofibrosis?
Which of the following is NOT considered a component of myelofibrosis?
Which mutation is associated with both Myelofibrosis and Essential Thrombocythemia?
Which mutation is associated with both Myelofibrosis and Essential Thrombocythemia?
Flashcards
JAK2 V617F mutation
JAK2 V617F mutation
A mutation commonly found in primary hematological malignancies like polycythemia vera.
Polycythaemia Rubra Vera (PRV)
Polycythaemia Rubra Vera (PRV)
A blood disorder characterized by increased red blood cell mass and JAK2 mutation.
Absolute polycythaemia
Absolute polycythaemia
An increase in red blood cell volume due to primary or secondary causes.
Relative polycythaemia
Relative polycythaemia
Signup and view all the flashcards
Essential Thrombocythemia (ET)
Essential Thrombocythemia (ET)
Signup and view all the flashcards
Myelofibrosis (MF)
Myelofibrosis (MF)
Signup and view all the flashcards
Chronic Myeloid Leukaemia (CML)
Chronic Myeloid Leukaemia (CML)
Signup and view all the flashcards
Bone Marrow Biopsy
Bone Marrow Biopsy
Signup and view all the flashcards
Hyperviscosity Syndrome
Hyperviscosity Syndrome
Signup and view all the flashcards
JAK2 mutation
JAK2 mutation
Signup and view all the flashcards
Symptoms of PV
Symptoms of PV
Signup and view all the flashcards
Diagnosis of PV
Diagnosis of PV
Signup and view all the flashcards
PV differential diagnosis
PV differential diagnosis
Signup and view all the flashcards
Treatment of PV
Treatment of PV
Signup and view all the flashcards
Lab findings in PV
Lab findings in PV
Signup and view all the flashcards
Clonal abnormality
Clonal abnormality
Signup and view all the flashcards
Megakaryocyte activity
Megakaryocyte activity
Signup and view all the flashcards
Bone marrow fibrosis
Bone marrow fibrosis
Signup and view all the flashcards
Leukoerythroblastic film
Leukoerythroblastic film
Signup and view all the flashcards
Myelofibrosis treatment
Myelofibrosis treatment
Signup and view all the flashcards
Extramedullary hematopoiesis
Extramedullary hematopoiesis
Signup and view all the flashcards
Progression to AML
Progression to AML
Signup and view all the flashcards
Myeloproliferative Disorders
Myeloproliferative Disorders
Signup and view all the flashcards
Polycythemia Vera
Polycythemia Vera
Signup and view all the flashcards
Essential Thrombocythemia
Essential Thrombocythemia
Signup and view all the flashcards
Primary Myelofibrosis
Primary Myelofibrosis
Signup and view all the flashcards
Risk of Acute Leukemia Transformation
Risk of Acute Leukemia Transformation
Signup and view all the flashcards
Clinical Manifestation of ET
Clinical Manifestation of ET
Signup and view all the flashcards
Platelet count in ET
Platelet count in ET
Signup and view all the flashcards
Diagnostic tests for ET
Diagnostic tests for ET
Signup and view all the flashcards
Differential Diagnosis for ET
Differential Diagnosis for ET
Signup and view all the flashcards
ET Treatments
ET Treatments
Signup and view all the flashcards
Primary Myelofibrosis (PMF)
Primary Myelofibrosis (PMF)
Signup and view all the flashcards
PDGF in PMF
PDGF in PMF
Signup and view all the flashcards
Study Notes
Myeloproliferative Disorders (MPD)
- MPDs are also known as myeloproliferative neoplasms (MPN)
- Characterized by the uncontrolled proliferation of one or more hematopoietic cell lines
- Includes excessive production of erythrocytes, granulocytes, and platelets
- Common in individuals over 50 years of age
- Often overlap in findings between different diseases
- Increased risk of transforming to acute leukemia
Specific MPDs
-
Polycythemia Vera (PV):
- Increased RBC (red blood cell) volume
- Often associated with a JAK2 V617F mutation
- Elevated hemoglobin and hematocrit levels
- Symptoms include headache, high blood pressure, and bleeding episodes
- Diagnosis involves full blood count, bone marrow biopsy, cytogenetics, and molecular analysis for JAK2 mutation
- Treatment includes myelosuppressive drugs like interferon or hydroxyurea, antihistamines, aspirin, and phlebotomy.
-
Essential Thrombocythemia (ET):
- Characterized by persistently high platelet count (often more than 600 x 109/L)
- Related to megakaryocyte proliferation and overproduction of platelets
- Common in 50-70-year-olds, with both sexes affected equally,
- Symptoms may include arterial thrombosis, hemorrhage, splenomegaly, and erythromelalgia.
- Diagnosed with a platelet count, bone marrow biopsy, cytogenetics, and molecular analysis for JAK2 mutation
- Treatment includes aspirin, chemotherapy (hydroxycarbamide), and anagrelide.
-
Primary Myelofibrosis (PMF):
- Progressive fibrosis (scar tissue) in the bone marrow that interferes with blood cell production (myeloid metaplasia)
- Resulting in extramedullary hematopoiesis in the spleen and liver.
- Thought to relate to increased release of growth factors (such as PDGF), from megakaryocytes
- Diagnosis involves full blood tests, bone marrow biopsy, cytogenetics, and molecular analysis for JAK2 mutation.
- Typically progresses over 4-5 years.
- Treatment may include anemia treatment, splenectomy, JAK2 inhibitor, chemotherapy, or allogeneic bone marrow transplant.
Overall Diagnosis and Treatment
- Diagnosis typically involves a variety of tests, including a full blood count, peripheral blood smear, bone marrow biopsy, cytogenetics, and molecular analysis like JAK2 mutation checking.
- Treatment strategy often varies according to the specific myeloproliferative disorder and an individual's condition.
- Different strategies include reducing blood cell production, addressing affected organs (like splenectomy), symptom management, or more invasive therapies like bone marrow transplant.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.